Randomized, double-blinded, multicenter, phase II study of pemetrexed, carboplatin, and Bevacizumab with enzastaurin or placebo in chemonaïve patients with stage IIIB/IV non-small cell lung cancer: Hoosier oncology group LUN06-116

Journal of Thoracic Oncology

Volumn 5, Issue 11, 2010, Pages 1815-1820

  Casey, Erin M ^a   Harb, Wael ^a,b   Bradford, Daniel ^c,d   Bufill, Jose ^c,e   Nattam, Sreenivasa ^c,f   Patel, Jyoti ^c,g   Fisher, William ^c,h   Latz, Jane E ⁱ   Li, Xiaochun ^a   Wu, Jingwei ^a   Hanna, Nasser ^a,c  

^a INDIANA UNIVERSITY   (United States)

^b Horizon Oncology   (United States)

^c Hoosier Oncology Group   (United States)

^d Highlands Oncology Group   (United States)

^e CCOP   (United States)

^f Fort Wayne Oncology and Hematology Inc   (United States)

^g NORTHWESTERN UNIVERSITY   (United States)

^h Medical Consultants   (United States)

ⁱ ELI LILLY AND COMPANY   (United States)

Author keywords

Bevacizumab; Enzastaurin; Non small cell lung cancer

Indexed keywords

BEVACIZUMAB; CARBOPLATIN; ENZASTAURIN; PEMETREXED; PLACEBO;

ADULT; ANEMIA; AREA UNDER THE CURVE; ARTICLE; BLEEDING; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER STAGING; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONGESTIVE HEART FAILURE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DIGESTIVE SYSTEM PERFORATION; DISEASE COURSE; DIVERTICULITIS; DOUBLE BLIND PROCEDURE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; DRUG WITHDRAWAL; EPISTAXIS; FATIGUE; FEMALE; HAZARD RATIO; HUMAN; HYPERTENSION; INTESTINE OBSTRUCTION; LOADING DRUG DOSE; LUNG EMBOLISM; LUNG HEMORRHAGE; LUNG NON SMALL CELL CANCER; MALE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA AND VOMITING; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL; SEPSIS; SIDE EFFECT; THROMBOCYTOPENIA; THROMBOEMBOLISM; TREATMENT OUTCOME; VEIN THROMBOSIS; WOUND DEHISCENCE;

EID: 78149467725     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0b013e3181ee820c     Document Type: Article

References (29)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2009. CA Cancer J Clin 2009;59:225-249.
2. Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. Non-small Cell Lung Cancer Collaborative Group. BMJ 1995;311:899-909.
3. Chemotherapy in addition to supportive care improves survival in advanced non-small-cell lung cancer: a systematic review and metaanalysis of individual patient data from 16 randomized controlled trials. J Clin Oncol 2008;26:4617-4625.
4. Spiro SG, Rudd RM, Souhami RL, et al. Chemotherapy versus supportive care in advanced non-small cell lung cancer: improved survival without detriment to quality of life. Thorax 2004;59:828-836.
5. Zinner RG, Fossella FV, Gladish GW, et al. Phase II study of pemetrexed in combination with carboplatin in the first-line treatment of advanced nonsmall cell lung cancer. Cancer 2005;104:2449-2456.
6. Scagliotti GV, Kortsik C, Dark GG, et al. Pemetrexed combined with oxaliplatin or carboplatin as first-line treatment in advanced non-small cell lung cancer: a multicenter, randomized, phase II trial. Clin Cancer Res 2005;11:690-696.
7. Gronberg BH, Bremnes R, Flotten O, et al. A phase III study by the Norwegian Lung Cancer Group: pemetrexed plus carboplatin vs. gemcitabine plus carboplatin as firstline chemotherapy in advanced nonsmall cell lung cancer. J Thorac Oncol 2009;27:3217-3224.
8. Scagliotti GV, Parikh P, von Pawel J, et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy- naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol 2008;26:3543-3551.
9. Herbst RS, Onn A, Sandler A. Angiogenesis and lung cancer: prognostic and therapeutic implications. J Clin Oncol 2005;23:3243-3256.
10. O'Byrne KJ, Koukourakis MI, Giatromanolaki A, et al. Vascular endothelial growth factor, platelet-derived endothelial cell growth factor and angiogenesis in non-small-cell lung cancer. Br J Cancer 2000;82:1427-1432.
11. Bremnes RM, Camps C, Sirera R. Angiogenesis in non-small cell lung cancer: the prognostic impact of neoangiogenesis and the cytokines VEGF and bFGF in tumours and blood. Lung Cancer 2006;51:143-158.
12. Jain RK, Duda DG, Clark JW, et al. Lessons from phase III clinical trials on anti-VEGF therapy for cancer. Nat Clin Pract Oncol 2006;3:24-40.
13. Sandler A, Gray R, Perry MC, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006;355: 2542-2550.
14. Reck M, von Pawel J, Zatloukal P, et al. Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAil. J Clin Oncol 2009; 27:1227-1234.
15. Patel JD, Hensing TA, Rademaker A, et al. Phase II study of pemetrexed and carboplatin plus bevacizumab with maintenance pemetrexed and bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer. J Clin Oncol 2009;27:3284-3289.
16. Gokmen-Polar Y, Murray NR, Velasco MA, et al. Elevated protein kinase C betaII is an early promotive event in colon carcinogenesis. Cancer Res 2001;61:1375-1381.
17. da Rocha AB, Mans DR, Regner A, et al. Targeting protein kinase C: new therapeutic opportunities against high-grade malignant gliomas? Oncologist 2002;7:17-33.
18. Shipp MA, Ross KN, Tamayo P, et al. Diffuse large B-cell lymphoma outcome prediction by gene-expression profiling and supervised machine learning. Nat Med 2002;8:68-74.
19. Graff JR, McNulty AM, Hanna KR, et al. The protein kinase Cbetaselective inhibitor, Enzastaurin (LY317615.HCl), suppresses signaling through the AKT pathway, induces apoptosis, and suppresses growth of human colon cancer and glioblastoma xenografts. Cancer Res 2005;65: 7462-7469.
20. Oberschmidt O, Eismann U, Schulz L, et al. Enzastaurin and pemetrexed exert synergistic antitumor activity in thyroid cancer cell lines in vitro. Int J Clin Pharmacol Ther 2005;43:603-604.
21. Schuette W. Pemetrexed in combination with cisplatin or carboplatin in the first line therapy of locally advanced or metastatic non-small cell lung cancer: a randomized, two-arm, parallel, open-label, multicentric phase II study. Eur J Cancer Suppl 2009;7:528; abstract P-9079, presented at 2009 ESMO Annual Meeting.
22. Oh Y, Herbst RS, Burris H, et al. Enzastaurin, an oral serine/threonine kinase inhibitor, as second- or third-line therapy of non-small cell lung cancer. J Clin Oncol 2008;26:1135-1141.
23. Obasaju CK, Raju RN, Stinchcombe T, et al. Final results of a randomized phase II trial of pemetrexed (P) + carboplatin (Cb) +/- enzastaurin (E) versus docetaxel (D)- Cb as first-line treatment of patients (pts) with stage IIIB/IV non-small cell lung cancer (NSCLC). J Clin Oncol 2009;27:(suppl; abstr 8037).
24. Herbst RS, O'Neill VJ, Fehrenbacher L, et al. Phase II study of efficacy and safety of bevacizumab in combination with chemotherapy or erlotinib compared with chemotherapy alone for treatment of recurrent or refractory non small-cell lung cancer. J Clin Oncol 2007;25:4743-4750.
25. Hainsworth J, Herbst R. A phase III, multicenter, placebo-controlled, double-blind, randomized clinical trial to evaluate the efficacy of bevacizumab (Avastin) in combination with erlotinib (tarceva) compared with erlotinib alone for treatment of advanced non-small cell lung cancer after failure of standard first-line chemotherapy (BETA). Plenary Session of Multidisciplinary Symposium in Thoracic Oncology, Chicago, IL, 2008.
26. Gandara DKE, Herbst RS, et al. S0536: Carboplatin, paclitaxel, cetuximab, and bevacizumab followed by cetuximab and bevacizumab maintenance in advanced non-small cell lung cancer (NSCLC): a SWOG phase II study. J Clin Oncol 2009;27:15s (abstr 8015).
27. Azad NS, Posadas EM, Kwitkowski VE, et al. Combination targeted therapy with sorafenib and bevacizumab results in enhanced toxicity and antitumor activity. J Clin Oncol 2008;26:3709-3714.
28. Sosman JAFK, Atkins MB, et al. Update results of phase I trial of sorafenib (S) and bevacizumab (B) in patients with metastatic renal cell cancer (mRCC). J Clin Oncol 2008;26:15s (abstr 5011).
29. BAY 43-9006 in Previously Untreated Patients With Non-Small Cell Lung Cancer (NSCLC). Protocol ID: NCT00533585. Available at: clinicaltrials.gov.